Literature DB >> 22865207

Bladder augmentation and urinary diversion for neurogenic LUTS: current indications.

Kamran P Sajadi1, Howard B Goldman.   

Abstract

Augmentation cystoplasty and urinary diversion are no longer commonplace in the management of patients with neurogenic bladder, but remain an important surgical treatment for those with refractory LUTS who have failed neuromodulation and onabotulinum toxin treatment or who are not candidates for those treatments. Augmentation is an option in patients who can perform intermittent catheterization and is usually performed with ileum or large intestine. Some patients benefit from continent cutaneous catherizable channels. Supravesical urinary diversion may be necessary in more severe cases. Ileovesicostomies are being supplanted by indwelling suprapubic catheters, and when catheters fail conduits may be a better option. When feasible, the diverted bladder should be excised to avoid pyocystis.

Entities:  

Mesh:

Year:  2012        PMID: 22865207     DOI: 10.1007/s11934-012-0271-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  30 in total

Review 1.  The past, present and future of augmentation cystoplasty.

Authors:  Suzanne M Biers; Suzie N Venn; Tamsin J Greenwell
Journal:  BJU Int       Date:  2011-11-25       Impact factor: 5.588

2.  Comparison of bladder rupture pressure after intestinal bladder augmentation (ileocystoplasty) and myomyotomy (autoaugmentation).

Authors:  D A Rivas; M B Chancellor; B Huang; A Epple; T E Figueroa
Journal:  Urology       Date:  1996-07       Impact factor: 2.649

3.  Fate of the leftover bladder after supravesical urinary diversion for benign disease.

Authors:  Tajammul Fazili; Tahir R Bhat; Shikohe Masood; John H Palmer; G R Mufti
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

4.  Application of appendicular-based cecal flap for less invasive augmentation cystoplasty: a novel technique.

Authors:  Saeed Shakeri; Alireza Aminsharifi; Zahra Jahanabadi
Journal:  Urol Int       Date:  2009-10-13       Impact factor: 2.089

5.  Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder.

Authors:  Jonathan H Watanabe; Jonathan D Campbell; Arliene Ravelo; Michael B Chancellor; Jonathan Kowalski; Sean D Sullivan
Journal:  Urology       Date:  2010-10       Impact factor: 2.649

6.  Follow-up of the remaining bladder after supravesical urinary diversion.

Authors:  E A Granados; J Salvador; J Vicente; H Villavicencio
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

7.  Outcome of gastrocystoplasty in tertiary pediatric urology practice.

Authors:  M P Leonard; N Dharamsi; P E Williot
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

8.  Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity.

Authors:  Priya Padmanabhan; Harriette M Scarpero; Douglas F Milam; Roger R Dmochowski; David F Penson
Journal:  World J Urol       Date:  2010-11-26       Impact factor: 4.226

9.  The fate of the remaining bladder following supravesical diversion.

Authors:  E B Eigner; F S Freiha
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

10.  Gastrocystoplasty: an alternative solution to the problem of urological reconstruction in the severely compromised patient.

Authors:  M C Adams; M E Mitchell; R C Rink
Journal:  J Urol       Date:  1988-11       Impact factor: 7.450

View more
  1 in total

Review 1.  The evaluation and management of refractory neurogenic overactive bladder.

Authors:  Raj Kurpad; Michael J Kennelly
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.